Immunotherapy plus targeted therapy for advanced mouth or throat cancer
Part of Cancer clinical trials.
This trial tests whether combining two medicines – sintilimab (an immunotherapy) and cetuximab (a targeted therapy) – given before and after surgery can help treat advanced mouth or throat cancer. The study aims to see if this approach is safe and effective for patients whose cancer has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer that starts in the mouth or the back of the throat (called oral or oropharyngeal cancer).
- Your cancer is 'locally advanced' – it has grown into nearby tissues but has not spread to distant organs.
- Your cancer cells have a certain protein (PD-L1) that the study drug targets. Your doctor will test for this.
- You have not had any previous treatment for this cancer.
- You are between 18 and 75 years old and are in generally good health.
- You are willing to use effective birth control during the study and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) before and after surgery for people whose mouth or throat cancer has returned after previous treatment. The goal is to see if this approach can help shrink or control the cancer and improve outcomes.
This trial tests whether giving immunotherapy (sintilimab) together with chemotherapy before surgery can help treat oral cavity cancer. The goal is to shrink the tumor and possibly improve outcomes for patients with early-stage cancer that hasn't spread.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
This Phase 2 trial tests giving the immunotherapy drug sintilimab before surgery, along with fewer chemotherapy cycles. The goal is to shrink or control oral or throat squamous cell cancers while keeping side effects lower, before the tumor is removed.
This trial tests whether adding a type of radiation therapy (SBRT) to chemoimmunotherapy before surgery helps people with advanced mouth or throat cancer. The goal is to see if this combination can shrink tumors more effectively and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.